Japan's Eisai Co. (ESALY, 4523.TO) will target a "huge unmet medical need" with its plan to begin selling the new diet drug Belviq in the U.S. in early 2013, the company's leader said Tuesday. Chief Executive Haruo Naito said Eisai will market the drug by aiming to enhance disease awareness, collaborate with patient groups and seek insurance coverage of Belviq. Obesity is "obviously a huge unmet medical need in this country," Mr. Naito said in an interview Tuesday. "It's a major medical expenditure and social cost."
